Japan’s Shionogi, creator of the blockbuster cholesterol treatment Crestor, announced on Monday, March 30, it would tie up with Ping An Insurance Group of China, selling a 2.05% voting stake for 33.53 billion yen (US$311 million).
Shionogi will form a joint venture with the Chinese group’s unit, Ping An Life Insurance of China Ltd, with the aim of discovering and distributing new drugs and developing generic ones as it looks to expand in China, reported Reuters.
“To attain our growth strategy beyond 2020, we must realize the expansion of our business in China, which is expected to show the greatest pharmaceutical market growth in the world over the next 10 years,” Shionogi said in the statement.
Shionogi, which gains roughly half its revenue from royalties, posted four-straight years of record operating profit through 2019. It focuses on infectious diseases but a looming patent cliff for its HIV treatments will create an earnings gap that will be hard to completely offset.
Ping An Insurance Group, China’s largest insurer by market value, said in February it expected the coronavirus outbreak to affect its business in the first half.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile’s Acquisition of Ka’ena Corporation Receives FCC Approval
Apr 26, 2024 by
CPI
UK Regulator Announces Two New Senior Executive Appointments
Apr 26, 2024 by
CPI
Paramount Global and Skydance Media Near Merger Deal, Eyeing CEO Change
Apr 26, 2024 by
CPI
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI